News Chart Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 01/09/2026 BST			5-day change	1st Jan Change
14.31 ^USD	+2.65%		-1.72%	-8.74%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

4593153af97dfd4.zqjjRO2OpyPK5SYHg8QIWxekJQ6LRvT9hIg97PvTWNk._piHdIzq4FK_1H9l95xQYlSQE2reKZWJwOptrZDkC66gkZMMu7eVZ6LUYw~308914a47fc4d081fa542b3cdafbc3eb